Search
Search Constraints
You searched for: Author/Creator Soisson, Lorraine A.Limit your search
- 615.372 1
- ALFQ Army Liposome formulation containing QS-21 -- CHMI controlled human malaria infection -- CI confidence interval -- CSP circumsporozoite protein -- ELISA enzyme-linked immunosorbent assay -- ELISpot enzyme-linked immunosorbent spot -- GMP good manufacturing process -- AE adverse event -- SAE Serious adverse event -- ILSDA inhibition of liver stage development assay -- MAAE medically attended adverse event -- PIMD potentially immune-mediated disease -- WRAIR Walter Reed Army Institute of Research -- 4WP1, 2WP3, 4WP2, 16WP3 4, 2 or 16 weeks post first, second or third vaccination -- MSD Meso Scale Diagnostics. 1
- Malaria Vaccine -- Circumsporozoite Protein -- Army Liposomal formulation -- ALFQ -- FMP013 -- Plasmodium -- Adjuvant -- Trial 1
- Vaccines -- Periodicals 1